 To this end, we undertook a Phase II clinical trial of neoadjuvant docetaxel Taxotere in patients with locally advanced breast cancer H-8448, with the primary goal of defining the clinical efficacy and the biologic effects of docetaxel. The secondary aim of the study was to identify distinctive gene expression patterns predictive of response to docetaxel chemotherapy. For this, we proposed to use microarray expression technology Affymetrix U95A and allied validation technologies e.g., IHC, western blot, quantitative RT-PCR to identify and validate patterns of gene expression associated with chemotherapy sensitivity or resistance. 